Clinical trials: Irinotecan
Colorectal Cancer, Metastatic Cancer
Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as floxuridine, dexamethasone, and irinotecan, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003753
- Testing
- dexamethasone, floxuridine, irinotecan hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Adenocarcinoma
Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer
The purpose of this study is to evaluate the efficacy of chemotherapy plus radiotherapy to patients with CA19-9-elevated Advanced Pancreatic Cancer who are not refractory to chemotherapy.
- Trial name
- PTCA199-11 (NCT06250972)
- Testing
- Gemcitabine, Nab-paclitaxel, Irinotecan, Intensity-Modulated Radiation Therapy (IMRT)
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Fudan University
Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Utility of ctDNA in Early Switch of First-line Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
The purpose of this study is to understand whether a blood-based test called circulating tumor DNA (ctDNA) can detect whether participants are having a desired tumor shrinkage or an undesired lack of tumor shrinkage, and to study…
- Trial name
- NCT07096362
- Testing
- 5-Fluorouracil, Oxaliplatin, Leucovorin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Miami
Colorectal Neoplasms
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or…
- Trial name
- OrigAMI-2 (NCT06662786)
- Testing
- Amivantamab, Cetuximab, 5-fluorouracil
- Where
- 239 sites in United States, Belgium and 20 more
- Volunteers
- 1,000 people
- Sponsor
- Janssen Research & Development, LLC
Colorectal Cancer
High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28
This trial aims to evaluate the efficacy, safety of high-dose FOLFIRI regimen in advanced colorectal cancer patients with wild-type UGT1A1*6 and *28.
- Trial name
- NCT03329183
- Testing
- Irinotecan
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shanghai Changzheng Hospital
Malignant Gliomas
Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas
Irinotecan has demonstrated activity in malignant gliomas in multiple phase II studies. The activity is limited, with an approximately 15 % response rate and a progression-free survival of 3-5 months.
- Trial name
- NCT00463073
- Testing
- Cetuximab, Bevacizumab, Irinotecan
- Where
- 3 sites in Denmark
- Volunteers
- 32 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Pediatric Cancer
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
This proof-of-concept platform trial is designed to cover the targeting of several survival pathways in oncogenesis that are currently not adequately employed for pediatric patients in Europe (Geoerger 2017; Geoerger 2019).
- Trial name
- ESMART (NCT02813135)
- Testing
- Ribociclib, Topotecan, Temozolomide
- Where
- 23 sites in Denmark, France and 4 more
- Volunteers
- 472 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Biliary Tract Cancer
Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies
This Phase II, single-arm, single-center study evaluates the conversion to resectability and safety of Ivonescimab combined with liposomal irinotecan and 5-FU/LV in patients with potentially resectable biliary tract malignancies.
- Trial name
- NCT06993025
- Testing
- Ivonescimab+chemotherapy
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Gastric Adenocarcinoma, Stage II Gastric Cancer
Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction
This phase II trial is studying how well giving irinotecan together with cisplatin works in treating patients who are undergoing surgical resection for locally advanced cancer of the stomach or gastroesophageal junction.
- Conditions
- Gastric Adenocarcinoma, Stage II Gastric Cancer, Stage III Gastric Cancer, Stage IV Gastric Cancer
- Trial name
- NCT00062374
- Testing
- Cisplatin, Computed Tomography, Fludeoxyglucose F-18
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004923
- Testing
- docetaxel, irinotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Yale University
Small Cell Lung Cancer Extensive Stage
Liposomal Irinotecan and Apatinib in ES-SCLC
The purpose of this study is to observe the efficacy and safety of liposomal irinotecan combined with apatinib in the treatment of extensive stage small cell lung cancer progressed from first-line regimen.
- Trial name
- LIAES (NCT06749691)
- Testing
- Liposomal Irinotecan and Apatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Colon Cancer (Stage II &Amp;Amp; III)
mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer
In patients with high-risk stage II and stage III colon cancer, curative surgery followed by adjuvant chemotherapy with FOLFOX or CAPOX regimens has become the standard treatment.
- Trial name
- OPTICAL-3 (NCT06890624)
- Testing
- cmFOLFOXIRI plus PD-1 inhibitor, mFOLFOX6
- Volunteers
- 138 people
- Sponsor
- Sun Yat-sen University
Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer
Precision Promise is a multi-center, seamless Phase 2/3 platform trial designed to evaluate multiple regimens in metastatic pancreatic cancer.
- Trial name
- NCT04229004
- Testing
- Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel
- Where
- 25 sites in United States
- Volunteers
- 502 people
- Sponsor
- Pancreatic Cancer Action Network
Esophageal Cancer
Fluorouracil, Irinotecan, Leucovorin, and Cisplatin as First-Line Therapy in Treating Patients With Metastatic Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, irinotecan, leucovorin, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00075738
- Testing
- cisplatin, fluorouracil, irinotecan hydrochloride
- Where
- 15 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Gastric Cancer Peritoneal Metastasis (GCPM)
A Sequential Trial of Low-Dose Radiotherapy Followed by Concurrent Immunotherapy, Systemic Chemotherapy, and Intraperitoneal Perfusion in Gastric Cancer With Peritoneal Carcinomatosis
This study is a prospective, single-center, open-label, exploratory phase II clinical trial aimed at evaluating the safety, tolerability, and preliminary efficacy of low-dose radiotherapy (LDR) sequentially combined with…
- Trial name
- NCT07784413
- Testing
- low-dose radiotherapy (LDR) sequentially combined with serplulimab, bevacizumab analog, and irinotecan or albumin-bound paclitaxel
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Advanced Colorectal Cancer (Part 1)
Clinical Trial Evaluating the Efficacy of Capecitabine Plus Lenvatinib in Patients With Advanced Colorectal Cancer Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidine
A New Treatment Opportunity for Patients with Advanced Colorectal Cancer Refractory to Standard Chemotherapy: Clinical Trial of Capecitabine plus Lenvatinib Combination Therapy
- Trial name
- LENCAP-CRC (NCT07683949)
- Testing
- Lenvanib (Lenvatinib),Xeloda (capecitabine)
- Where
- South Korea
- Volunteers
- 93 people
- Sponsor
- Seoul National University Bundang Hospital
Colorectal Cancer
An Observational Study of Continued Bevacizumab Plus Chemotherapy Until First Progression in Participants With Metastatic Colorectal Cancer (CRC)
This prospective, multicenter, observational study will investigate the effectiveness and safety of bevacizumab in routine clinical practice in participants with metastatic CRC.
- Trial name
- AVACONT (NCT02305615)
- Testing
- Bevacizumab, Chemotherapy
- Where
- 22 sites in Hungary
- Volunteers
- 300 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer
The purpose of this study is to determine whether irinotecan, S-1, and bevacizumab are safe in the treatment of unresectable or recurrent colorectal cancer
- Trial name
- NCT00569790
- Testing
- S-1, Irinotecan, Bevacizumab
- Where
- Japan
- Volunteers
- 53 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00042874
- Testing
- alvocidib, irinotecan hydrochloride, fluorouracil
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer Metastatic
Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis
This is a non-randomized, open-label, single-center clinical trial to evaluate efficacy and safety of sintilimab plus bevacizumab and chemotherapy on treatment in patients with advanced no liver metastatic MSS/pMMR colorectal…
- Trial name
- NCT06973343
- Testing
- Group A, Group B
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Anhui Provincial Cancer Hospital